Physician profile
Ravinder Kaur
NPI 1952936346
$743.46
in general payments reported to CMS, 2019-2025
17 companies · $460 in 2025
The $460 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $29.56 · 2022: $49.00 · 2023: $83.22 · 2024: $122 · 2025: $460.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $665.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $664.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $178.41 | 2023-2025 | Jardiance, Ofev |
| Novartis Pharmaceuticals Corporation | $92.86 | 2023-2025 | |
| Xeris Pharmaceuticals, INC. | $65.73 | 2021-2024 | Gvoke Hypopen, Recorlev |
| Lilly USA, LLC | $59.59 | 2025 | Zepbound, Mounjaro |
| Amgen INC. | $43.26 | 2025 | Evenity, Prolia |
| Otsuka America Pharmaceutical, INC. | $41.96 | 2025 | Rexulti |
| Novo Nordisk INC | $29.24 | 2022-2023 | |
| Merck Sharp & Dohme LLC | $27.94 | 2023-2025 | Gardasil 9, M-M-R II, Pneumovax 23 |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $27.80 | 2025 | Caplyta |
| Lundbeck LLC | $27.46 | 2025 | Rexulti |
| Glaxosmithkline, LLC. | $25.29 | 2025 | Trelegy Ellipta |
| Seqirus USA INC | $24.83 | 2024 | Fluad, Flucelvax |
| Takeda Pharmaceuticals U.S.A., INC. | $23.97 | 2025 | Trintellix |
| Kowa Pharmaceuticals America, INC. | $22.31 | 2025 | Zoryve |
| Bayer Healthcare Pharmaceuticals INC. | $19.14 | 2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $18.26 | 2025 | |
| Abbvie INC. | $15.41 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ravinder Kaur listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.